Toggle SGML Header (+)


Section 1: 8-K (FORM 8-K)

herc20200108_8k.htm

 


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 


 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

January 8, 2020

 

 
Hercules Capital, Inc.
(Exact name of registrant as specified in its charter)

 

Maryland 

814-00702 

74-3113410 

(State or other jurisdiction

of incorporation)

(Commission File No.)

(I.R.S. Employer

Identification No.)

     

400 Hamilton Ave., Suite 310

Palo Alto, CA

 

94301

(Address of principal executive offices)

 

(Zip Code)

 


Registrant's telephone number, including area code: (650) 289-3060

 

Not Applicable

(Former name or address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

 

 

 

Common Stock, par value $0.001 per share

HTGC

New York Stock Exchange

5.25% Notes due 2025

HCXZ

New York Stock Exchange

6.25% Notes due 2033

HCXY

New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company          ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.             ☐

 


 

 

 

 

Item 8.01 Other Events 

 

On January 8, 2020, Hercules Capital, Inc. issued a press release announcing its many select investment milestones and operating highlights for 2019. The text of the press release is included as an exhibit to this Form 8-K.

 

Item 9.01 Financial Statements and Exhibits 

 

(d)    Exhibits

   

99.1

Press Release dated January 8, 2020.

 

 

 

 

SIGNATURES 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HERCULES CAPITAL, INC.

       

January 8, 2020 

     
   

By:

 /s/ Melanie Grace                               

     

 Melanie Grace

     

 General Counsel

 

(Back To Top)

Section 2: EX-99.1 (EXHIBIT 99.1)

ex_168977.htm

Exhibit 99.1

 

 

 

Hercules Capital Highlights 2019 Achievements, Setting a New Investment Record with $1.47 Billion in Total New Debt and Equity Commitments

 

 

PALO ALTO, Calif., January 8, 2020 Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest specialty financing provider to innovative venture, growth and established stage companies backed by top-tier venture capital and select private equity firms, today announced select investment milestones and operating highlights for 2019.

 

“Following a strong fourth quarter, we recently completed a second consecutive record-breaking year with new investment commitments totaling $1.47 billion,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “We also established new records for total new investment fundings, total shareholder distributions and total investment portfolio dollar growth in 2019. These 2019 accomplishments, among others, are a result of the outstanding efforts of our team and the strength of our venture debt and growth capital platform. It has been a truly remarkable year for the Company and all stakeholders.”

 

Bluestein continued, “This year would not have been possible without the unwavering dedication, commitment and expertise of our world-class employees and the ongoing support of the numerous partners, management teams, entrepreneurs and venture capital and financial sponsors that we partner with on a daily basis. We approach the new year with optimism and an unrelenting focus on continuing to deliver best-in-class results. We are truly grateful and thank you for your continued trust.”   

 

 

Full-Year 2019 Select Major Achievements and Highlights

 

Delivered Record New Debt and Equity Commitments

 

 

Record total new debt and equity commitments of $1.47 billion, as of December 31, 2019

 

 

Surpassed $9.7 billion in cumulative debt commitments since inception

 

Enhanced the Balance Sheet with Several Strategic Capital Market Raising Activities

 

 

Issued $105.0 million of 4.77% 5-year Institutional Notes due 2024

 

 

Issued $250.0 million of 4.703% Asset-backed Notes due 2028

 

 

Completed $70.5 million Common Stock Offering, accretive to NAV

 

 

Completed $62.7 million ATM net proceeds, accretive to NAV, as of December 30, 2019

 

 

Completed new $200.0 million credit facility with MUFG Union Bank

 

1

 

 

Corporate Events Led by Key Management Appointments & Promotions

 

 

Scott Bluestein appointed Chief Executive Officer in July

 

 

Seth Meyer appointed Chief Financial Officer in February

 

 

R. Bryan Jadot promoted to Head of Life Sciences Venture Lending in May

 

 

Steve Kuo promoted to Head of Technology Venture Lending in May

 

 

Received BBB Investment Grade Credit and Corporate Rating from DBRS

 

 

Received BBB+ Investment Grade Credit and Corporate Rating from KBRA

 

 

Increased the Company’s base cash distribution to $0.32 per share – the first increase since 2013

 

Numerous Achievements from Hercules’ Innovative Portfolio Companies

 

 

Record 12 IPO events

 

 

10 completed M&A events

 

 

Raised in excess of $5.0 billion of new equity capital

 

 

Continued strong execution across the Hercules Life Sciences portfolio

 

 

o

5 new drugs and devices launched into the market

 

 

o

5 NDAs and BLAs filed

 

 

o

7 positive pivotal trials across the Life Sciences portfolio

 

About Hercules Capital, Inc.

 

Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $9.7 billion to over 480 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.

 

Hercules’ common stock trades on the New York Stock Exchange (NYSE) under ticker symbol HTGC. In addition, Hercules has two retail bond issuances of 5.25% Notes due 2025 (NYSE: HCXZ) and 6.25% Notes due 2033 (NYSE: HCXY).

 

2

 

 

Forward-Looking Statements

 

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act.

 

The information disclosed in this press release is made as of the date hereof and reflects Hercules’ most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Hercules believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

 

Contact:

 

Michael Hara                                   

Investor Relations and Corporate Communications          

Hercules Capital, Inc.                

(650) 433-5578                              

[email protected]

 

3

 

(Back To Top)